Several new therapies are transforming diabetes management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted potential candidates. Retatrutide, fast and rapid weight loss products a dual GIP and GLP-1 site agonist, exhibits significant body mass decrease and improved blood sugar levels. Cagrillintide, another GLP-1 ag